• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Sutter Hill Ventures

BioCentury | Jul 5, 2022
Deals

TeneoBio shareholders gain another exit as AstraZeneca buys spinout

Pharma adds bispecific with purchase of TeneoTwo, bringing more returns to shareholders, including Lightspeed and Sutter Hill
Read More
BioCentury | Jul 1, 2022
Finance

After Forty Seven takeout, MacQuitty finding ‘freedom’ with Lightspeed team 

Hybrid firm’s ‘leap’ backing Stanford spinout spurred more life sciences deals, with onetime Abingworth partner building team and portfolio
Read More
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more 

Escient raises $77.5M B roundEscient Pharmaceuticals Inc. announced Monday the start of a Phase I/Ib trial of lead program EP547 for cholestatic and uremic pruritis alongside a $77.5 million series B
Read More
BioCentury | Jun 29, 2018
Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Read More
BioCentury | Jun 28, 2018
Financial News

Tricida gains, others dip after upsized IPOs

Read More
BioCentury | Oct 20, 2017
Finance

Early opportunity

How Forty Seven plans to spend its $75M series B
Read More
BioCentury | Oct 20, 2017
Financial News

Forty Seven raises $75M series B

Read More
BioCentury | Oct 18, 2017
Financial News

Forty Seven raises $75M series B

Read More
BioCentury | Jul 21, 2017
Emerging Company Profile

Targeting APOE4

How E-Scape is changing APOE4’s structure to treat AD
Read More
BioCentury | Jul 15, 2017
Finance

E-scape's expansion

What neurology play E-Scape plans to do with its $63M series A round
Read More
Items per page:
1 - 10 of 75